1. Home
  2. PIM vs EQ Comparison

PIM vs EQ Comparison

Compare PIM & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Master Intermediate Income Trust

PIM

Putnam Master Intermediate Income Trust

HOLD

Current Price

$3.10

Market Cap

153.2M

Sector

Finance

ML Signal

HOLD

Logo Equillium Inc.

EQ

Equillium Inc.

HOLD

Current Price

$2.21

Market Cap

157.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PIM
EQ
Founded
1988
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.2M
157.4M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PIM
EQ
Price
$3.10
$2.21
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.00
AVG Volume (30 Days)
46.6K
816.7K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
8.28%
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$61.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.07
$0.46
52 Week High
$3.50
$3.54

Technical Indicators

Market Signals
Indicator
PIM
EQ
Relative Strength Index (RSI) 41.59 37.32
Support Level $3.07 $1.68
Resistance Level $3.33 $2.61
Average True Range (ATR) 0.05 0.21
MACD -0.01 -0.05
Stochastic Oscillator 21.43 11.53

Price Performance

Historical Comparison
PIM
EQ

About PIM Putnam Master Intermediate Income Trust

Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: